CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 128 filers reported holding CRINETICS PHARMACEUTICALS IN in Q1 2023. The put-call ratio across all filers is 0.00 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,868,446 | +746.4% | 62,826 | +357.1% | 0.00% | – |
| Q2 2023 | $220,745 | 0.0% | 13,745 | 0.0% | 0.00% | – |
| Q1 2023 | $220,745 | -53.7% | 13,745 | -47.3% | 0.00% | – |
| Q4 2022 | $477,008 | -99.9% | 26,066 | 0.0% | 0.00% | – |
| Q3 2022 | $511,936,000 | +99.7% | 26,066 | +89.6% | 0.00% | – |
| Q2 2022 | $256,344,000 | -22.3% | 13,745 | -8.5% | 0.00% | – |
| Q1 2022 | $329,711,000 | -49.5% | 15,021 | -34.6% | 0.00% | – |
| Q4 2021 | $652,634,000 | +92.1% | 22,972 | +42.3% | 0.00% | – |
| Q3 2021 | $339,747,000 | +11.7% | 16,140 | 0.0% | 0.00% | – |
| Q2 2021 | $304,239,000 | +37.3% | 16,140 | +11.3% | 0.00% | – |
| Q1 2021 | $221,606,000 | +8.3% | 14,503 | 0.0% | 0.00% | – |
| Q4 2020 | $204,637,000 | +24.3% | 14,503 | +38.1% | 0.00% | – |
| Q3 2020 | $164,582,000 | -71.8% | 10,503 | -68.4% | 0.00% | – |
| Q2 2020 | $582,610,000 | – | 33,254 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 2,030,616 | $31,028,000 | 6.04% |
| 5AM Venture Management, LLC | 1,362,286 | $20,816,000 | 3.75% |
| Burrage Capital Management LLC | 272,393 | $4,162,000 | 3.37% |
| Altium Capital Management LP | 361,930 | $5,530,000 | 1.54% |
| Vivo Capital, LLC | 2,214,138 | $33,832,000 | 1.19% |
| Bain Capital Life Sciences Investors, LLC | 1,071,428 | $16,371,000 | 0.93% |
| Perceptive Advisors | 3,659,381 | $51,606,000 | 0.65% |
| New Leaf Venture Partners, L.L.C. | 141,000 | $2,154,000 | 0.50% |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 2,003,688 | $30,616,000 | 0.45% |
| Opaleye Management Inc. | 188,000 | $2,873,000 | 0.42% |